Whitepaper
Parameter Sensitivity with GastroPlus
10 Jul 2024
en
Accelerating Timelines with Predictive Intelligence
Integrating in-silico PBPK modeling into early drug development enables more informed decisions across CMC and clinical strategy.
Supports early evaluation of absorption, distribution, metabolism, and transport risks.
Early identification of absorption risks allows teams to refine dose selection and timelines.
Perform in vitro–in vivo extrapolation to predict drug absorption and systemic exposure.
Crystal Pharmatech provides PBPK modeling and simulation using GastroPlus®, one of the pharmaceutical industry's most widely adopted platforms.
By integrating experimental physicochemical data with mechanistic physiological models, GastroPlus® enables accurate prediction of drug exposure and formulation impacts.
GastroPlus® is a registered trademark of Simulation Plus, Inc.
Solubility and pKa-dependent dissolution behavior prediction.
Systemic absorption and metabolism pathways simulation.
Drug transport mechanisms and tissue distribution analysis.
PBPK modeling supports faster and more informed development decisions by enabling early prediction of clinical pharmacokinetics and dosing strategies.
Tissue-specific solubility and drug distribution across complex physiological environments.
Advanced pharmacokinetic models using mechanistic and non-compartmental analysis approaches.
Dosing strategies by evaluating species differences, formulation effects, and dosing routes.
Have a question or need support with your project? Please complete the form, and our team will get back to you shortly.
Our capabilities span three specialized platforms:
Small Molecule
Crystal Bio Solutions
Crystal NAX
By providing your e-mail address, you agree to receive an e-mail response from Crystal Pharmatech to your inquiry. The information you submit will be governed by our Privacy Policy.
Subscribe to be the first to get the updates!